Equities Analysts Offer Predictions for SWTX Q1 Earnings

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) – Equities researchers at Wedbush lowered their Q1 2025 EPS estimates for SpringWorks Therapeutics in a research note issued to investors on Thursday, February 20th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.84) per share for the quarter, down from their previous estimate of ($0.75). Wedbush has a “Outperform” rating and a $81.00 price objective on the stock. The consensus estimate for SpringWorks Therapeutics’ current full-year earnings is ($2.05) per share. Wedbush also issued estimates for SpringWorks Therapeutics’ Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($2.81) EPS, FY2026 earnings at ($0.22) EPS and FY2027 earnings at $2.90 EPS.

SpringWorks Therapeutics (NASDAQ:SWTX) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.38). The company had revenue of $61.55 million during the quarter, compared to analyst estimates of $60.53 million. SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%.

Several other equities analysts have also weighed in on SWTX. HC Wainwright reaffirmed a “buy” rating and set a $74.00 target price on shares of SpringWorks Therapeutics in a report on Friday. Evercore ISI lifted their price objective on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. Finally, Guggenheim decreased their price objective on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $71.50.

SpringWorks Therapeutics Trading Down 2.7 %

Shares of NASDAQ:SWTX opened at $58.29 on Monday. SpringWorks Therapeutics has a 12-month low of $28.21 and a 12-month high of $62.00. The business has a 50 day moving average of $41.10 and a two-hundred day moving average of $37.70. The company has a market capitalization of $4.34 billion, a PE ratio of -16.75 and a beta of 0.81.

Insider Activity at SpringWorks Therapeutics

In other SpringWorks Therapeutics news, insider Daniel Pichl sold 29,750 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $54.36, for a total transaction of $1,617,210.00. Following the completion of the transaction, the insider now owns 50,762 shares of the company’s stock, valued at $2,759,422.32. This represents a 36.95 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Saqib Islam sold 48,000 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $53.30, for a total value of $2,558,400.00. Following the completion of the transaction, the chief executive officer now owns 1,002,502 shares in the company, valued at approximately $53,433,356.60. This trade represents a 4.57 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 313,822 shares of company stock valued at $16,802,876. 7.61% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Huntington National Bank grew its holdings in shares of SpringWorks Therapeutics by 38.2% during the fourth quarter. Huntington National Bank now owns 694 shares of the company’s stock worth $25,000 after buying an additional 192 shares in the last quarter. AlphaQuest LLC boosted its position in SpringWorks Therapeutics by 70.2% during the fourth quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock worth $36,000 after acquiring an additional 414 shares during the last quarter. Venturi Wealth Management LLC purchased a new stake in SpringWorks Therapeutics during the 4th quarter valued at about $45,000. State of Wyoming raised its holdings in SpringWorks Therapeutics by 39.5% in the 4th quarter. State of Wyoming now owns 1,530 shares of the company’s stock valued at $55,000 after acquiring an additional 433 shares during the last quarter. Finally, GF Fund Management CO. LTD. acquired a new stake in SpringWorks Therapeutics in the 4th quarter valued at about $56,000.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.